Feliciana Mariotti
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Linagliptin is a risk factor for bullous pemphigoid associated with BP180-NC16A/BP230 seronegativity and milder severity: Evidence from a prospective case-control study supporting ECD-BP180 enzyme-linked immunosorbent assay in reducing diagnostic delay.
Journal: Journal of the American Academy of Dermatology
Published: February 16, 2026
A case series of immune checkpoint inhibitor-induced bullous pemphigoid successfully treated with dupilumab and evidence for the BP180 midportion epitope as a preferential autoantigenic target.
Journal: Frontiers in medicine
Published: January 28, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.
Journal: Acta dermato-venereologica
Published: January 09, 2026
Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients.
Journal: Acta dermato-venereologica
Published: January 09, 2026
Bullous pemphigoid associated with canagliflozin intake.
Journal: Italian journal of dermatology and venereology
Published: October 03, 2025
BP230-Type Bullous Pemphigoid is a Rare Subset of Bullous Pemphigoid Associated With a Favorable Prognosis: A Retrospective Analysis From a Tertiary Referral Center.
Journal: International journal of dermatology
Published: September 16, 2025
Autoantibodies to α6 Integrin Subunit Are Detected in a Cohort of Italian Oral Pemphigoid Patients.
Journal: International journal of dermatology
Published: May 05, 2025
Clinical Improvement of Bullous Pemphigoid with Hyperkeratosis and Palmoplantar Keratoderma in Two Patients Treated with Dupilumab.
Journal: Acta dermato-venereologica
Published: September 11, 2024
Bullous pemphigoid and mucous membrane pemphigoid humoral responses differ in reactivity towards BP180 midportion and BP230.
Journal: Frontiers in immunology
Published: September 10, 2024
Evidence of a Dose-Dependent Phenotypic Effect of the Desmoplakin (DSP) c.273+5G > A Variant in a Child With Palmoplantar Keratoderma and Woolly Hair Association.
Journal: Experimental dermatology
Published: August 10, 2024
COVID-19 Vaccine: A Potential Risk Factor for Accelerating the Onset of Bullous Pemphigoid.
Journal: Vaccines
Published: July 26, 2024
Indirect immunofluorescence for the diagnosis of bullous pemphigoid and mucous membrane pemphigoid patients: human or monkey salt-split skin sections.
Journal: International journal of dermatology
Published: May 15, 2024
Last Updated: 09/26/2026